ClinicalTrials.gg
RecruitingNCT06029491TURBOUpdated Oct 21, 2026

Thrombectomy Using Pulsed Aspiration for Reperfusion of Brain Occlusions

An interventional study of RapidPulseTM Aspiration System in Acute Ischemic Stroke, sponsored by RapidPulse, Inc. Recruiting at 30 sites in 4 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2026-10-21.

Sponsored by RapidPulse, Inc · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Mar 2025; still recruiting 1 year 7 months later.
Updated Oct 21, 2026Site recruiting status changedPrimary completion moved+4 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
170
Allocation
Not applicable
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 480 studies in Ischemic Stroke with a site in United States — 120 open to participants now, 145 under way, 13 of them phase 3. Ischemic Stroke · United States.

Planned enrollment
113th of 364
170 · median 65
Started
2025
with 23 others
No phase
183 of 480
51 open now
Primary completion
2027-06
later than 60 of 144 live
Registered
385th of 480
by date

Among the 480 studies in Ischemic Stroke with a site in United States, this one is the 113th largest by planned enrollment of the 364 interventional ones that give a count, is one of 24 that started in 2025, is one of 183 with no phase, reaches primary completion later than 60 of the 144 other live ones, and was the 385th registered.

Ischemic Stroke

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

120 of the 480 studies in Ischemic Stroke with a site in United States are open now. Recruiting first, the newest first:

115 more — sign in →

All 120 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 480 studies in Ischemic Stroke with a site in United States, or all of them as a file.
02

Study summary

The goal of this clinical trials is to demonstrate the safety and effectiveness for the RapidPulseTM Aspiration System in patients experiencing acute ischemic stroke within 8 hours of symptom onset or last seen normal. Subjects will undergo mechanical thrombectomy (a procedure to remove a clot in the brain which is preventing blood flow), with the RapidPulseTM Aspiration System. Participation in the trial is for 90 days.

Read the detailed description

The purpose of this prospective, open label clinical trials is to demonstrate the safety and effectiveness for the RapidPulseTM Aspiration System as frontline approach in the treatment of large vessel occlusions in patients experiencing Acute Ischemic Stroke within 8 hours of symptom onset or last seen normal. The target sample size for this clinical trial is 170 subjects enrolled in up to 40 sites globally. The maximum number of subjects that may be enrolled is 340. Subjects will undergo mechanical thrombectomy procedure and will have postoperative assessments completed at 24 hours and on day 5-7 or hospital discharge (whichever comes first). The final study visit will occur approximately 90 days after the index event. The primary effectiveness endpoint is the proportion of patients who achieve modified treatment in cerebral infarction score (mTICI) ≥ 2b, based on the best mTICI score within a maximum of 3 passes where only aspiration with the Study Device was used without rescue, as assessed by an independent Imaging Core Lab. The primary safety endpoint is the proportion of patients with symptomatic ICH (sICH) at 24 hours post-thrombectomy as assessed by an independent central events committee (CEC).

03

Conditions studied

  • Acute Ischemic Stroke

Keywords

  • Stroke
  • Large Vessel Occlusion
  • Mechanical Thrombectomy
  • Neurovascular Intervention
04

Who can participate

The criteria were revised on the registry on Oct 21, 2026. See what changed

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age 18 to 85 years
  • Clinical diagnosis of acute ischemic stroke with NIH Stroke Scale (NIHSS) score ≥ 6
  • Able to be treated within 8 hours of symptom onset or last known normal (LKN)
  • Able to be treated within 120 minutes from the time of the qualifying baseline CT/MR image
  • Pre-morbid Modified Rankin Scale (mRS) score 0-1
  • Angiographic confirmation of large vessel occlusion (LVO) in the anterior (intracranial ICA or MCA M1 or M2 segments) or posterior circulation (vertebral or basilar arteries) as confirmed by digital subtraction angiography (DSA) irrespective of IV thrombolysis administration
  • Candidate to receive treatment with ADAPT technique (Direct Aspiration First-Pass Technique)

Exclusion criteria

Exclusion Criteria:

  • Intracranial Hemorrhage (ICH)
  • Significant mass effect and/or midline shift
  • Alberta Stroke Program Early CT Score (ASPECTS) \<6 or (PC-ASPECTS \<8 on CT angiography source images or DWI MRI for posterior circulation stroke)
  • Intracranial Atherosclerotic Disease (ICAD)
  • Multiple or tandem occlusions
  • less than 6 months
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
170 participants (estimated)

Study arms

  • Experimental
    Treatment Arm

    Each subject will undergo baseline evaluation for acute ischemic stroke due to large vessel occlusion, per standard of care and undergo mechanical thrombectomy procedure, aspiration to remove the thrombus in the neuro-vasculature using the RapidPulseTM Aspiration System.

    Device: RapidPulseTM Aspiration System

Interventions

  • DeviceRapidPulseTM Aspiration System

    The RapidPulseTM Aspiration System is designed to remove occlusive thrombus from the occluded cerebral vasculature using precisely pulsed aspiration. The system is comprised of the multi-use, non-sterile RapidPulseTM Aspiration Pump, the single use, sterile RapidPulseTM Tube set, the single use, non-sterile RapidPulseTM Collection Canister and the single use, sterile RapidPulseTM 071 Catheter.

    Also known as: Aspiration Thrombectomy, Thrombectomy

06

What researchers measure

Primary outcomes

  1. Rate of perfusion success using only the study device.

    The proportion of patients who achieve mTICI ≥ 2b within a maximum of 3 passes where only aspiration with the Study Device was used without rescue, as assessed by an independent Imaging Core Lab.

    Time frame: Intra-procedural

  2. Rate of symptomatic intracranial hemorrhage (sICH)

    The proportion of patients with symptomatic ICH (sICH) at 24 hours post-thrombectomy

    Time frame: Post-procedural (24 hours post-thrombectomy)

Secondary outcomes

  1. Modified Rankin Scale (mRS) at 90 days post treatment

    Proportion of patients who achieve mRS ≤2 at 90-days post treatment.

    Time frame: Post-procedure (90 days post-thrombectomy)

Other outcomes

  1. Rate of modified First Pass Reperfusion Effect (mFPE) after one reperfusion attempt

    Modified First Pass Reperfusion Effect (mFPE) as defined by mTICI ≥ 2c after one device pass

    Time frame: Intra-procedural

  2. Rate of modified First Pass Reperfusion Effect (mFPE) after one reperfusion attempt

    Modified First Pass Reperfusion Effect (mFPE) as defined by mTICI ≥ 2b after one device pass

    Time frame: Intra-procedural

  3. Final reperfusion effect

    Final mTICI ≥ 2b after all passes (including any rescue therapy) at procedure conclusion

    Time frame: Intra-procedural

  4. Time to reperfusion

    Time from arterial puncture (procedure initiation) to achieve mTICI ≥ 2b using first line aspiration treatment.

    Time frame: Intra-procedural

  5. Rate of major early neurological recovery

    Proportion of patients with major early neurological recovery at 24-hours as defined by reduction in National Institutes of Health Stroke Scale (NIHSS) score from baseline of at least 8 points or reaching NIHSS 0-1. \*NIHSS ranges from 0 to 42, with higher scores indicating greater neurological deficit.

    Time frame: Post-procedure (24 hours post-thrombectomy)

  6. Rate of major early neurological recovery

    Change in NIHSS score from Baseline to 24 hours

    Time frame: 24 hours

  7. Incidence of Adverse Events (AEs)

    All recorded adverse events as assessed by the independent CEC.

    Time frame: Intra-procedural to post-procedure (through 90 days post-thrombectomy)

  8. Incidence of Serious Adverse Events (SAEs)

    All device-related and procedure-related serious adverse events as assessed by the independent CEC.

    Time frame: Intra-procedural to post-procedure (through 90 days post-thrombectomy)

  9. Incidence of all cause mortality

    All-cause mortality assessed through 90 days post index procedure.

    Time frame: Intra-procedural to post-procedure (through 90 days post-thrombectomy)

  10. Incidence of device related vasospasm

    Device-related vasospasm

    Time frame: Intra-procedural

  11. Incidence of embolism in new territory

    Embolism in new territory determined based on procedural angiogram

    Time frame: Intra-procedural

  12. Incidence of all intracranial hemorrhage

    Any intracranial hemorrhage according to the Heidelberg classification at 24-hours

    Time frame: Post-procedural (24 hours post-thrombectomy)

07

Study locations

21 of 30 sites recruiting
  • Providence Saint John's Medical Foundation
    Torrance, California 90503, United States
    Recruiting
    • Jason Tarpley, MD · Principal investigator
  • Yale University
    New Haven, Connecticut 06519, United States
    Recruiting
    • Charles Matouk, MD · Principal investigator
  • Baptist Health Research Institute
    Jacksonville, Florida 32207, United States
    Recruiting
    • Amin Aghaebrahim, MD · Principal investigator
  • University of South Florida
    Tampa, Florida 33620, United States
    Recruiting
    • Maxim Mokin, MD · Principal investigator
  • Emory University at Grady
    Atlanta, Georgia 30303, United States
    Recruiting
    • Jonathan Grossberg, MD · Principal investigator
  • Rush University Medical Center
    Chicago, Illinois 60612, United States
    Recruiting
    • Michael Chen, MD · Principal investigator
  • Advocate Aurora Research Institute
    Park Ridge, Illinois 60068, United States
    Recruiting
    • Michael Young, MD · Principal investigator
  • Indiana University Health
    Indianapolis, Indiana 46202, United States
    Not yet recruiting
    • Bradley Bohnstedt, MD · Principal investigator
  • State University of Iowa
    Iowa City, Iowa 52242, United States
    Recruiting
    • Edgar Samaniego, MD · Principal investigator
  • Washington University
    St Louis, Missouri 63110, United States
    Recruiting
    • Arindam Chatterjee, MD · Principal investigator
  • Cooper Health System
    Camden, New Jersey 08103, United States
    Not yet recruiting
    • Jane Khalife, MD · Principal investigator
  • State University of New York at Buffalo
    Buffalo, New York 14203, United States
    Recruiting
    • Jason Davies, MD · Principal investigator
  • Icahn School of Medicine at Mount Sinai
    New York, New York 10029, United States
    Recruiting
    • Tomoyoshi Shigematsu, MD · Principal investigator
  • UPMC
    Pittsburgh, Pennsylvania 15213, United States
    Active, not recruiting

    Not enrolling at this site — choose another above.

  • Prisma Health
    Greenville, South Carolina 29601, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Semmes Murphey Foundation - Baptist Memorial Hospital
    Memphis, Tennessee 38120, United States
    Recruiting
    • Nitin Goyal, MD · Principal investigator
  • Vanderbilt University Medical Center
    Nashville, Tennessee 37232, United States
    Withdrawn

    Not enrolling at this site — choose another above.

  • Valley Baptist Medical Center - Harlingen
    Harlingen, Texas 78550, United States
    Recruiting
    • Ameer Hassan, DO · Principal investigator
  • Centre Hospitalier Universitaire de Bordeaux
    Bordeaux, 33000, France
    Not yet recruiting
    • Gaultier Marnat, MD · Principal investigator
  • Centre Hospitalier Universitaire de Montpellier
    Montpellier, 34295, France
    Not yet recruiting
    • Vincent Costalat, MD · Principal investigator
  • Centre Hospitalier Universitaire de Toulouse
    Toulouse, 31059, France
    Not yet recruiting
    • Christophe Cognard, MD · Principal investigator
  • Hospital General Universitario Dr. Balmis
    Alicante, 03010, Spain
    Recruiting
    • José Ignacio Gallego, MD · Principal investigator
  • Hospital Universitari Germans Trias i Pujol
    Badalona, 08916, Spain
    Recruiting
    • Sebastià Remollo, MD · Contact
    • Sebastià Remollo, MD · Principal investigator
  • Hospital Universitari Vall d' Hebron
    Barcelona, 08035, Spain
    Recruiting
  • Hospital Universitari de Bellvitge
    Barcelona, 08907, Spain
    Recruiting
  • Hospital Universitari de Girona Dr. Josep Trueta
    Girona, 17007, Spain
    Not yet recruiting
    • Mikel Terceno Izaga, MD · Principal investigator
  • Hospital Universitario de la Princesa
    Madrid, 28006, Spain
    Recruiting
    • María del Carmen Ramos Martín, MD · Principal investigator
    • José Luis Caniego, MD · Principal investigator
  • Hospital Universitario 12 de Octubre
    Madrid, 28041, Spain
    Recruiting
    • Federico Ballenilla, MD · Principal investigator
  • Hospital Universitario La Paz
    Madrid, 28046, Spain
    Recruiting
    • Pedro Navia, MD · Principal investigator
  • Istanbul Aydan Universitesi VM Medical Park Florya Hastanesi
    Istanbul, 34295, Turkey (Türkiye)
    Recruiting
    • Arsida Bajrami Geyik, MD · Principal investigator
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2025 (actual). Primary completion is estimated for Jun 2027, 27 months after the start.

Of 80 industry-sponsored interventional studies with no phase under Ischemic Stroke, half reached primary completion within 24 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 46. This study's planned 27 months is above that.

Counting every sponsor, half of 656 studies reached it within 27 months; a quarter within 14 and three quarters within 48.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 21, 2026: primary completion Jan 2027 → Jun 2027 and completion Apr 2027 → Sep 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 1, 2023
First posted
Sep 8, 2023
StartActual
Mar 27, 2025
Primary completionEst.
Jun 2027was Jan 2027
CompletionEst.
Sep 2027was Apr 2027
Last update
Oct 21, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
6 sites changed recruiting status (6 now recruiting)
Show 6 sites
  • Yale University · New Haven, United StatesNot yet recruiting→Recruiting
  • Advocate Aurora Research Institute · Park Ridge, United StatesNot yet recruiting→Recruiting
  • State University of Iowa · Iowa City, United StatesNot yet recruiting→Recruiting
  • Washington University · St Louis, United StatesNot yet recruiting→Recruiting
  • Icahn School of Medicine at Mount Sinai · New York, United StatesNot yet recruiting→Recruiting
  • Semmes Murphey Foundation - Baptist Memorial Hospital · Memphis, United StatesNot yet recruiting→Recruiting
Oct 21, 2026
Primary completion
Jan 2027→Jun 2027
Oct 21, 2026
Study completion
Apr 2027→Sep 2027
Oct 21, 2026
Eligibility
Maximum age 80 Years→85 Years; 1 inclusion criterion edited; 1 exclusion criterion edited, 1 added
What changed in the criteria
Inclusion criteria
  • EditedAge 18 to 8085 years
Exclusion criteria
  • AddedSignificant mass effect and/or midline shift
  • EditedAlberta Stroke Program Early CT Score (ASPECTS) <6 or (PC-ASPECTS <8 on CT angiography source images or DWI MRI for posterior circulation stroke)
Oct 21, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • ChangedBefore Rate of First Pass Reperfusion Effect (FPE)Now Rate of perfusion success using only the study device.Time frame: Intra-procedural
Oct 21, 2026
Secondary outcomes
3 added, 1 removed, 2 description edited
What changed in the outcomes
  • RemovedRate of reperfusion after all study device passesTime frame: Intra-procedural
  • Addedother outcomeRate of modified First Pass Reperfusion Effect (mFPE) after one reperfusion attemptTime frame: Intra-procedural
  • Addedother outcomeRate of major early neurological recoveryTime frame: 24 hours
  • Addedother outcomeIncidence of Adverse Events (AEs)Time frame: Intra-procedural to post-procedure (through 90 days post-thrombectomy)
  • Descriptionother outcomeIncidence of Serious Adverse Events (SAEs): how it is measured was reworded
  • Descriptionother outcomeRate of modified First Pass Reperfusion Effect (mFPE) after one reperfusion attempt: how it is measured was reworded
Oct 21, 2026
Title
The Pivotal Study of RapidPulseTM Aspiration System→Thrombectomy Using Pulsed Aspiration for Reperfusion of Brain Occlusions
Oct 21, 2026
Show all 1 update
  1. Oct 21, 2026
    6 sites changed recruiting status (6 now recruiting)
    Show 6 sites
    • Yale University · New Haven, United StatesNot yet recruiting→Recruiting
    • Advocate Aurora Research Institute · Park Ridge, United StatesNot yet recruiting→Recruiting
    • State University of Iowa · Iowa City, United StatesNot yet recruiting→Recruiting
    • Washington University · St Louis, United StatesNot yet recruiting→Recruiting
    • Icahn School of Medicine at Mount Sinai · New York, United StatesNot yet recruiting→Recruiting
    • Semmes Murphey Foundation - Baptist Memorial Hospital · Memphis, United StatesNot yet recruiting→Recruiting
    Primary completion Jan 2027→Jun 2027
    Study completion Apr 2027→Sep 2027
    Eligibility Maximum age 80 Years→85 Years; 1 inclusion criterion edited; 1 exclusion criterion edited, 1 added
    What changed in the criteria
    Inclusion criteria
    • EditedAge 18 to 8085 years
    Exclusion criteria
    • AddedSignificant mass effect and/or midline shift
    • EditedAlberta Stroke Program Early CT Score (ASPECTS) <6 or (PC-ASPECTS <8 on CT angiography source images or DWI MRI for posterior circulation stroke)
    Primary outcomes 1 edited
    What changed in the outcomes
    • ChangedBefore Rate of First Pass Reperfusion Effect (FPE)Now Rate of perfusion success using only the study device.Time frame: Intra-procedural
    Secondary outcomes 3 added, 1 removed, 2 description edited
    What changed in the outcomes
    • RemovedRate of reperfusion after all study device passesTime frame: Intra-procedural
    • Addedother outcomeRate of modified First Pass Reperfusion Effect (mFPE) after one reperfusion attemptTime frame: Intra-procedural
    • Addedother outcomeRate of major early neurological recoveryTime frame: 24 hours
    • Addedother outcomeIncidence of Adverse Events (AEs)Time frame: Intra-procedural to post-procedure (through 90 days post-thrombectomy)
    • Descriptionother outcomeIncidence of Serious Adverse Events (SAEs): how it is measured was reworded
    • Descriptionother outcomeRate of modified First Pass Reperfusion Effect (mFPE) after one reperfusion attempt: how it is measured was reworded
    Title The Pivotal Study of RapidPulseTM Aspiration System→Thrombectomy Using Pulsed Aspiration for Reperfusion of Brain Occlusions
    + 2 other changes: verification date and description

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06029491
Lead sponsor
RapidPulse, Inc
Responsible party
Sponsor
First posted
Sep 8, 2023
Start date
Mar 27, 2025
Primary completion
Jun 2027 (estimated)
Completion
Sep 2027 (estimated)
Last update
Oct 21, 2026

Study contacts

Cynthia Yang
Contact
cyang@rapidpulsemed.com
9498367402
Raul G Nogueira, MD
principal investigator · University of Pittsburgh Medical Center Stroke Institute
Marc Ribó, MD
principal investigator · Hospital Universitari Vall d' Hebron

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion